A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Luspatercept (Primary) ; Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Acronyms ODYSSEY
- Sponsors GSK
Most Recent Events
- 26 Mar 2025 Protocol amended to change phase from phase 2 to phase 1/2.
- 26 Mar 2025 Planned End Date changed from 25 Aug 2026 to 13 Nov 2026.
- 26 Mar 2025 Planned primary completion date changed from 14 Aug 2026 to 14 Oct 2026.